Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong-Reference-Cited by-同舟云学术

Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong

Published:2019-04-16 Issue:4 Volume:14 Page:e0215279
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Bouttell Janet^ORCID,Teoh Jeremy,Chiu Peter K.,Chan Kevin S.,Ng Chi-Fai,Heggie Robert^ORCID,Hawkins Neil

Funder

Health and Medical Research Fund

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P et al; members of the EAU–ESTRO–ESUR–SIOG Prostate Cancer Guidelines Panel. EAU–ESTRO–ESUR–SIOG Guidelines on Prostate Cancer. https://uroweb.org/guideline/prostate-cancer/ accessed 15 March 2019

2. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume;P Chiu;International Urology And Nephrology,2016

3. Prostate cancer in Asia: a collaborative report;R Chen;Asian J Urol,2014

4. Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening Study;B Le;The Journal Of Urology,2010

5. The Prostate Health Index: a new test for the detection of prostate cancer;S Loeb;Therapeutic Advances In Urology,2013

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A 2‐year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort;BJU International;2024-07-04

2. Economic evaluation of prostate cancer risk assessment methods: A cost‐effectiveness analysis using population data;Cancer Medicine;2023-09-23

3. Current prostate cancer screening and treatment strategies may not support a holistic nationwide program;Cancer;2022-06

4. Prostate health index (PHI) as a reliable biomarker for prostate cancer: a systematic review and meta-analysis;Clinical Chemistry and Laboratory Medicine (CCLM);2022-05-16

5. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis;Value in Health;2022-01